Literature DB >> 16530195

Efficacy and safety of cordocentesis for prenatal diagnosis.

Can Liao1, Jiaxue Wei, Qiuming Li, Lixian Li, Jian Li, Dongzhi Li.   

Abstract

OBJECTIVE: To assess the efficacy and safety of diagnostic cordocentesis.
METHODS: Between January 1991 and May 2004, 2,010 cordocentesis were performed in the outpatient setting in 2,010 women with singleton pregnancies. A fixed needle guide and a 22-gauge percutaneous needle were used and no more than 2 attempts were allowed at 1 visit. In most cases, the umbilical vein was the target vessel. The results of each procedure and pregnancy outcomes were recorded and analyzed.
RESULTS: The most frequent indication for cordocentesis was risk of severe thalassemia (59.0%), followed by a need for rapid karyotyping (30.0%). Most of the procedures (97%) were performed in the free cord loop and the remaining at the cord insertion. The overall success rate was 98.4%, with 80.0% of the successful procedures performed at the first needle insertion and the remaining 20% at the second insertion. Transient bleeding was observed at the puncture site in 19.8% of cases and transient fetal bradycardia in 4.9% of cases. The total fetal loss and cordocentesis-related loss rates within 2 weeks of cordocentesis were 2.7% and 1.0%, respectively, before 24 weeks of gestation and 1.9% and 0.8% after 24 weeks. The other obstetric complications were unremarkable.
CONCLUSIONS: Cordocentesis is a simple, safe, and reliable procedure for prenatal diagnosis.

Entities:  

Mesh:

Year:  2006        PMID: 16530195     DOI: 10.1016/j.ijgo.2006.01.005

Source DB:  PubMed          Journal:  Int J Gynaecol Obstet        ISSN: 0020-7292            Impact factor:   3.561


  8 in total

1.  High-throughput discovery and characterization of fetal protein trafficking in the blood of pregnant women.

Authors:  Jill L Maron; Gil Alterovitz; Marco Ramoni; Kirby L Johnson; Diana W Bianchi
Journal:  Proteomics Clin Appl       Date:  2009-12       Impact factor: 3.494

2.  Rapid Flow cytometric prenatal diagnosis of primary immunodeficiency (PID) disorders.

Authors:  Anju Mishra; Maya Gupta; Aparna Dalvi; Kanjaksha Ghosh; Manisha Madkaikar
Journal:  J Clin Immunol       Date:  2014-02-18       Impact factor: 8.317

3.  Efficacy of Antenatal Intravenous Immunoglobulin Treatment in Pregnancies at High Risk due to Alloimmunization to Red Blood Cells.

Authors:  Beate Mayer; Larry Hinkson; Wiebke Hillebrand; Wolfgang Henrich; Abdulgabar Salama
Journal:  Transfus Med Hemother       Date:  2018-10-31       Impact factor: 3.747

Review 4.  The application of in utero magnetic resonance imaging in the study of the metabolic and cardiovascular consequences of the developmental origins of health and disease.

Authors:  Stephanie A Giza; Simran Sethi; Lauren M Smith; Mary-Ellen E T Empey; Lindsay E Morris; Charles A McKenzie
Journal:  J Dev Orig Health Dis       Date:  2020-12-14       Impact factor: 2.401

5.  MR Imaging-derived Oxygen-Hemoglobin Dissociation Curves and Fetal-Placental Oxygen-Hemoglobin Affinities.

Authors:  Reut Avni; Ofra Golani; Ayelet Akselrod-Ballin; Yonni Cohen; Inbal Biton; Joel R Garbow; Michal Neeman
Journal:  Radiology       Date:  2016-01-14       Impact factor: 11.105

6.  Ultrasound Measurements of Fetal Thyroid: Reference Ranges from a Cohort of Low-Risk Pregnant Women.

Authors:  R M Barbosa; K C Andrade; C Silveira; C M Almeida; R T Souza; P F Oliveira; Jose Guilherme Cecatti
Journal:  Biomed Res Int       Date:  2019-12-17       Impact factor: 3.411

7.  Risk of mother-to-child transmission of hepatitis B virus after fetal blood sampling: a report of six cases.

Authors:  Zhenyan Han; Yuan Zhang; Jin Zhou; Qingqing Wang; Yonghua Huang; Hongying Hou
Journal:  BMC Infect Dis       Date:  2021-07-30       Impact factor: 3.090

8.  Introducing the non-invasive prenatal testing for detection of Down syndrome in China: a cost-effectiveness analysis.

Authors:  Wenru Shang; Yang Wan; Jianan Chen; Yanqiu Du; Jiayan Huang
Journal:  BMJ Open       Date:  2021-07-06       Impact factor: 2.692

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.